Lupus Science & Medicine

Article	Citations
2021 DORIS definition of remission in SLE: final recommendations from an international task force	97
Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lprmice	52
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials	45
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways	35
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies	32
Thoughts on COVID-19 and autoimmune diseases	31
SARS-CoV-2 vaccines in patients with SLE	29
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to ac	28
Living with systemic lupus erythematosus in 2020: a European patient survey	27
Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials	25
Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review	25
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus	25
Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review	24
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis	23
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria	20
Impact of COVID-19 pandemic on SLE: beyond the risk of infection	20
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015	19
Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus	19
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis	19
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis	18
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis	18
Herpes zoster in SLE: prevalence, incidence and risk factors	18
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data	18
Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study	17
Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus	17

Towards a practical management of fatigue in systemic lupus erythematosus	17
Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease	17
LLDAS is an attainable treat-to-target goal in childhood-onset SLE	16
Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries	16
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus	15
Associations of metabolic syndrome in SLE	15
Phenotypical changes and clinical significance of CD4+/CD8+T cells in SLE	15
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway	14
Discoid lupus erythematosus skin lesion distribution and characteristics in Black patients: a retrospective cohort study	14
Overcoming barriers to recruitment and retention of African–American women with SLE in behavioural interventions: lessons learnt from the WELL study	14
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus	14
High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index	14
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis	13
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis	13
Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE	13
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus	13
Infection hospitalisation in systemic lupus in Sweden	12
Loss of antiphospholipid antibody positivity post-thrombosis in SLE	12
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study	12
Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015	12
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes	12
Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial	11
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	11
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study	11
Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort	11
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis	11
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus	10
Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations	10
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen	10
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	10
Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus	10
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus	10
Clinical and histopathological features of myositis in systemic lupus erythematosus	10
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	10
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre	10
Atherosclerosis in SLE: a potential role for serum parathormone levels	10
Jaccoud-type lupus arthropathy: practical classification criteria	9
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis	9
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study	9
Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus	9
Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need	9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	9
TNIP1/ABIN1 and lupus nephritis: review	9
Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016–2018	9
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	9
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)	8
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE	8
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study	8
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis	8
Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies	8

ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases	8
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study	8
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus	8
LUPUS-BEST—treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial	8
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort	8
Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis	8
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE	8
Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus	7
Candidate drug replacements for quinacrine in cutaneous lupus erythematosus	7
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials	7
Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study	7
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis	7
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme	7
Cell-bound complement activation products associate with lupus severity in SLE	7
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus	7
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients	7
Breastfeeding in women with rheumatic diseases	7
Impact of severe infections in SLE: an observational study from the Spanish national registry	7
Cutaneous vasculitis in SLE	7
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research	7
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence	7
Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety	6
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome	6
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	6
Anti-Müllerian hormone in African-American women with systemic lupus erythematosus	6
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus	6
Rheumatologists’ perspective on hydroxychloroquine guidelines	6
Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections	6
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study	6
Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells	6
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin	6
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks	6
Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus	6
Cutaneous lupus concerns from the patient perspective: a qualitative study	6
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	6
Cross-sectional study of the effects of self-efficacy on fatigue and pain interference in black women with systemic lupus erythematosus: the role of depression, age and education	5
Evaluation of structured data from electronic health records to identify clinical classification criteria attributes for systemic lupus erythematosus	5
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus	5
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler	5
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials	5
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort	5
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	5
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE	5
Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives	5
Gender differences in SLE: report from a cohort of 417 Caucasian patients	5
Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus	5
Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus	5
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network	5
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	5
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria	5
Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations	5
Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study	5
Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force	5
Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus	5
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus	5
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study	4
Development and implementation of a virtual Lupus Patient Education Event during the COVID-19 pandemic	4
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	4
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state	4
Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study	4
Efficacy and safety of rituximab biosimilar in refractory lupus	4
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial	4
Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus	4
Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis	4
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	4
Could severe COVID-19 be considered a complementopathy?	4
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study	4
Molecular endotypes of type 1 and type 2 SLE	4
Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis	4
Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial	4
Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review	4
Molecular signatures of intrarenal complement receptorsC3AR1andC5AR1correlate with renal outcome in human lupus nephritis	4
Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity	4
Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand	4
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	4
Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse	4
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development	4
Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases	3
Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis	3
Urine proteomic insights from the belimumab in lupus nephritis trial	3

Coping with systemic lupus erythematosus in patients’ words	3
Human leucocyte antigens profiling in Malay female patients with systemic lupus erythematosus: are we the same or different?	3
Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model	3
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	3
Intermuscular adipose tissue in patients with systemic lupus erythematosus	3
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	3
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study	3
Immune gene expression and functional networks in distinct lupus nephritis classes	3
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic	3
Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor	3
Intracellular homocysteine metabolites in SLE: plasma S-adenosylhomocysteine correlates with coronary plaque burden	3
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	3
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine	3
Different indirect immunofluorescence ANA substrate performance in a diagnostic setting of patients with SLE and related disorders: retrospective review and analysis	3
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients	3
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study	3
Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity	3
Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis	3
Study of common hypertriglyceridaemia genetic variants and subclinical atherosclerosis in a group of women with SLE and a control group	3
Clinical associations of cognitive dysfunction in systemic lupus erythematosus	3
Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study	3
Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort	3
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies	3